Background {#Sec1}
==========

Vaccination is one of the major contributors to the global improvement of health and life expectancy \[[@CR1], [@CR2]\]. The success of vaccination programmes is dependent on a high uptake, which is currently threatened globally by an increase in vaccine hesitancy and refusal \[[@CR3]--[@CR6]\]. Since 2012, a decline in vaccine uptake has also been observed in The Netherlands, a country with high uptake rates historically \[[@CR7]\]. To counter this decline, it is crucial to understand the importance of individual determinants of vaccine decision-making.

Determinants of vaccine decision-making have been studied thoroughly over the past years, revealing factors like (perceived) vaccine safety, risk perception, (perceived) vaccine effectiveness, and social norms and beliefs (for example religious or anthroposophical) \[[@CR6], [@CR8]--[@CR11]\]. Multiple factors account for the recent decline in vaccine uptake, but two of the main drivers are lower vaccine confidence and risk perception, the latter referring to the perceived severity and susceptibility of vaccine-preventable diseases. Vaccine confidence is associated with the belief in vaccine effectiveness and safety \[[@CR9], [@CR12]\]. Risk perception is affected by the successes of vaccination programmes in the past, which have markedly decreased the incidence of many vaccine-preventable diseases. In this situation, individuals may increasingly become complacent to the threat and burden of these infectious diseases \[[@CR13]--[@CR15]\]. Closely linked to the concepts of risk perception and vaccine confidence is "freeriding" behaviour, i.e. relying on the vaccination of others and the effect of herd immunity to protect oneself \[[@CR16]\], implying that high coverage leads to rational refusal of vaccination. This purely rational behaviour has been observed within experimental settings, where participants played so-called vaccination games \[[@CR17]\]; however multiple observational studies have found evidence against this assumption \[[@CR18], [@CR19]\].

The Dutch vaccination programme consists of vaccinations that target different age and risk groups, including children, adolescents, pregnant women, clinical risk groups and elderly. It is likely that these different groups have a different inclination towards vaccination, based on different perspectives on individual risk and expectations with regard to future health. For example, an adult member of a risk group may have entirely different considerations than an adolescent, or a parent who has to make the decision about vaccinating a young child. Discrete choice experiments (DCE) have been used to study vaccine decision-making, both in The Netherlands and elsewhere \[[@CR20]--[@CR22]\]. These studies focussed either on adults taking decisions for themselves or on parents deciding for their children. None of these studies used the same DCE for both groups, hindering a direct comparison of preferences. Therefore, we have used a similar experimental design enabling a comparative study of vaccine decision-making between these two groups in The Netherlands.

Methods {#Sec2}
=======

We employed a recently developed DCE design that was used in a study about vaccine decision-making in Flanders and South Africa \[[@CR23], [@CR24]\]. This choice design presented respondents with 10 choice sets of two hypothetical profiles of an unknown (general) vaccine against an unknown disease. For each choice set, respondents had to indicate their preferred vaccine profile. Besides respondents' answers to the choice tasks, we gathered information on socio-economic factors as well as health literacy, in order to be able to explore the results for different groups. The survey was conducted in June--July 2018 among Dutch speaking adults in The Netherlands who are part of an online (registered) consumer panel. Recruitment of participants followed pre-defined sample quotas regarding background characteristics (Table [1](#Tab1){ref-type="table"}). Sample quotas for gender and age were defined based on national statistics \[[@CR25]\]. Generally, orthodox Protestants have a lower vaccine uptake due to religious beliefs \[[@CR26]--[@CR28]\]. To be able to capture their preferences, at least 10% of the respondents came from municipalities where more than 5% of the inhabitants voted for the orthodox Protestant political party (SGP) during the 2017 national elections \[[@CR29]\]. Finally, for the purpose of being able to compare the decision with regard to a child to the decision for oneself we used a predefined sample quota of 50% inclusion of parents of at least one child below 18. Only one respondent per household could participate. Table 1Comparison of sample characteristics with pre-defined sample quota and population statisticsCharacteristicAdult group *N* = 825 (%)Child group *N* = 722 (%)Sample *N* = 1547 (%)Dutch population (%)^a^Predefined quota *N* = 1500 (%)**Gender** Male55.040.048.049.049.0 Female45.060.052.051.051.0**Age group** 18--3422.832.427.326.026.0 35--4914.250.731.228.628.6 50--6532.716.225.026.626.6 66--8530.30.716.518.818.8**Educational level** Low21.912.917.731.4 Medium44.846.045.438.2NA High33.241.136.928.9**Province** Drenthe2.32.92.62.9 Flevoland1.71.71.72.4 Friesland44.44.23.8 Gelderland12.19.410.912.0 Groningen3.55.54.53.4 Limburg6.96.56.76.5 Noord-Brabant16.814.015.514.7NA Noord-Holland13.817.915.716.5 Overijssel6.37.66.96.7 Utrecht7.56.66.97.5 Zeeland2.71.92.32.2 Zuid-Holland21.220.120.721.4 Missing1.11.41.2**Biblebelt**17.19.813.73.010.0**Cultural background** Dutch90.488.289.4 Western European3.83.63.7NA Other5.88.26.9**Household** Living alone23.6--12.6 Living alone with children3.816.99.9 Living together without children40.8--21.8NA Living together with children23.983.151.5 Other7.9--4.2**Health literacy (SBSQ) \> 2**91.190.790.9NANA^a^Source: Statistics Netherlands

We divided study participants in two groups, referred to as the 'oneself' and 'child' group. Respondents without children under 18 years of age could only be allocated to the 'oneself' group, remaining respondents were randomly allocated to either the 'oneself' or 'child' group. The 'oneself' group answered questions on vaccinating themselves, the 'child' group on vaccinating their youngest child. As an incentive for participation, respondents received credit rewards, transferable into coupons or air miles.

The questionnaire consisted of five parts involving (1) background characteristics of the respondent; (2) vaccine-related attitudes; (3) the DCE; (4) risk perception of infectious diseases and (5) health literacy. The full questionnaire is available in the Additional Material [1](#MOESM1){ref-type="media"}.

Background characteristics included: gender; age; 4-digit postal code; level of education; household composition; family size (number of children); age of youngest child; mother\'s country of birth; professional experience in the healthcare sector; previous exposure to severe diseases; eligibility for influenza vaccination (i.e. belonging to a risk group that qualifies for annual vaccination via the GP); past acceptance of influenza vaccination (if eligible); smoking status; beliefs that influence (attitude towards) vaccination decisions; religious background; and past acceptance of National Immunization Programme (NIP) vaccination for one's children (if any).

The second part, surveying vaccine-related attitudes, contained 21 statements, each focussed on a particular aspect of the vaccination programme. These statements were adopted from a selection of previously conducted questionnaires on vaccine decision behaviour of parents as well as elderly \[[@CR12], [@CR22], [@CR30]\]. All statements had to be answered on a 5-point Likert scale (mostly ranging from strongly disagree to strongly agree).

The third part, the DCE, assigned each respondent to 10 choice sets of two unlabelled vaccine profiles. To capture all main and interaction effects, we created a design of 50 choice sets, divided into five subsets of 10 choice sets, using a Bayesian D-optimal design \[[@CR31]\]. The subsets were distributed randomly and evenly among the participants in both the 'oneself' and 'child' group. Each choice task was composed of six attributes, but only the levels of three of them differed between the two alternatives. These differences were made explicit by marking them in yellow. Respondents were, however, asked to take the levels of all attributes into account \[[@CR31]--[@CR34]\]. The attributes included were vaccine effectiveness, burden of disease for which the vaccine protects, vaccine-related side-effects (VRSE), accessibility of vaccination; population coverage and local coverage. Attributes were selected based on literature on DCEs in the context of vaccination \[[@CR18]--[@CR20], [@CR35]--[@CR38]\] and health economics in general \[[@CR18]--[@CR20], [@CR32], [@CR35]--[@CR40]\], as well as qualitative studies. A focus group study (*n* = 16), pilot study (*n* = 41) and a soft launch with free-form feed-back (*n* = 184) in the original Flemish target population resulted in the final selection and finetuning of the six attributes. Attributes as burden of disease, vaccine effectiveness, VRSE and accessibility are utilized frequently in DCE studies in the field of vaccination. Vaccine coverage, both at the population and the local level, is included less often in vaccine DCEs, although its importance is well described in literature about behavioural change models \[[@CR41]\]. For the full description of the survey design, we refer the interested reader to \[[@CR24]\]. The attributes and levels of the DCE are shown in Table [2](#Tab2){ref-type="table"}. Table 2DCE attributes and levelsAttributeLevel description1. Vaccine effectivenessa) Protects **50%** of vaccinated individualsb) Protects **90%** of vaccinated individuals2. Burden of diseasea) The disease, against which the vaccine protects is **rare** and often **mild**: hospitalization is exceptional and the disease is not life-threateningb) The disease, against which the vaccine protects is **rare** and often **severe**: often with hospitalization and the disease is life-threateningc) The disease, against which the vaccine protects is **common** and often **mild**: hospitalization is exceptional and the disease is not life-threateningd) The disease, against which the vaccine protects is **common** and often **severe**: often with hospitalization and the disease is life-threatening3. VRSEa) Mild side-effects are **common** and severe side-effects are highly unlikelyb) Mild side-effects **rarely occur** and severe side-effects are highly unlikely4. Accessibilitya) The vaccine is **free of charge** and provided by the GP, well baby clinic or occupational physicianb) The vaccine is **not reimbursed** and is only available with a prescription5. Local coveragea) **30%** of your acquaintances (friends and family) is already vaccinatedb) **60%** of your acquaintances (friends and family) is already vaccinatedc) **90%** of your acquaintances (friends and family) is already vaccinated6. Population coveragea) **30%** of the Dutch population is already vaccinatedb) **60%** of the Dutch population is already vaccinatedc) **90%** of the Dutch population is already vaccinated

The fourth part of the questionnaire assessed the participants' perception of the relative severity of and susceptibility of themselves or their child for measles, influenza, a urinary tract infection and leukaemia \[[@CR42]\]. Also, respondents had to indicate from which sources they received information or whom they would consult regarding vaccination decisions.

Finally, the respondents' health literacy was assessed using Chew's Set of Brief Screening Questions (SBSQ), which is a validated subjective measure of health literacy containing three items: 'How confident are you filling out forms by yourself?' (Confident with Forms), 'How often do you have someone (like a family member, friend, hospital/clinic worker or caregiver) help you read hospital materials?' (Help Read), and 'How often do you have problems learning about your medical condition because of difficulty understanding written information?' (Problems Reading) \[[@CR43]--[@CR45]\]. Responses were scored on a 5-point Likert scale ranging from 0 (always or not certain at all) to 4 (never or completely certain). A total score, taken as the mean over the three items, with a value of ≤2 indicates inadequate health literacy \[[@CR43]--[@CR45]\].

Note that the entire questionnaire was identical for the 'oneself' and 'child' group except for the framing of the subject of interest with respect to the vaccination decision (oneself or one's child). As indicated, the design of our Dutch DCE was identical to the design of the South African DCE \[[@CR23]\], which was an improved version of the design used in Flanders \[[@CR24]\]. The design was explicitly developed to be used for cross-country comparisons. The additional background questions of our study were, however, tailored to the Dutch situation, as was the addition of health literacy items. Our changes to the original questionnaires were reviewed and accepted by the Ethical Committee of the Antwerp University Hospital (UZA, Belgium), granting ethical clearance to perform this study (Reference number: 15/2/12).

The relative importance of the attributes and the relative utility values attached to the attribute levels were obtained by a Panel Mixed Logit (PML) model using Hierarchical Bayes estimation. To accommodate for unobserved preference heterogeneity of the respondents, we assumed normally distributed preference parameters without correlation between attributes. We ran 10,000 Bayesian iterations, and used the last 5000 for estimation. The total utility of a vaccination alternative is the sum of the attributes' main and interaction effect estimates. Overall significance of the attributes was computed by likelihood ratio (LR) tests and relative importance of each attribute by the normalized logworth statistic (*−log*~10~ (*p*-value of the LR-test)). Based on the finding that both coverage attributes depict a linear trend, we used linear coding for these attributes. Therefore, the estimates for these attributes represent the marginal change in utility when vaccination coverage increases by 10%. The DCE results were analysed using the Choice Modelling platform of JMP Pro 14 \[[@CR46]\].

We estimated the a priori PML model consisting of all main attribute effects and all two-way interactions between an attribute and 'vaccine effectiveness', 'VRSE' and 'accessibility', for both the 'oneself' and 'child' group. We explored structural differences in observed preference heterogeneity among groups of respondents by estimating all two-way interactions between the vaccine attributes and the background characteristics, attitudes towards vaccination, risk perception and health literacy questions in separate models. Next, we studied all individually significant two-way interactions in a joint model, where we iteratively dropped all insignificant covariates until we obtained a joint model consisting of only significant terms. As final step we removed interaction terms with a relative importance below a normalized logworth value of 4.

Results {#Sec3}
=======

The final dataset consisted of 1547 respondents, divided into the 'oneself' group (*n* = 825) and the 'child' group (*n* = 722). The study sample was representative of the general Dutch population with respect to the background characteristics gender, age and province. There was an underrepresentation of individuals with lower educational attainment. The 'oneself' and the 'child' groups differed slightly with regard to age and gender (see Table [1](#Tab1){ref-type="table"}) because assignment to the 'child' group was conditional on being a parent of a child below 18 years, which is closely tied to the age of the parent. With regard to health literacy, 90*.*9% of the total sample had a health literacy mean score above the threshold set by Chen et al. (*\>* 2), indicating that the vast majority of the respondents were health literate (Table [1](#Tab1){ref-type="table"}).

With regard to all respondents, both in the 'oneself' and the child group, with children below 18 years old (*N* = 855), 85.5% report that they fully vaccinated their child (ren) following the NIP guidelines, 6.5% did not vaccinate, 5.7% vaccinated their child(ren) partially and the remaining indicated 'n/a' (2.3%). Based on dichotomized 5-point Likert responses on three statements ('Vaccinating myself/my child against infectious diseases is wise', 'Vaccinating myself/my child against infectious disease is important', 'Vaccinating myself/my child against infectious diseases is necessary), at least 80% of the parents in the 'child' group indicated a positive attitude towards vaccination for each statement separately, whereas this held for 75% in the 'oneself' group. Table [3](#Tab3){ref-type="table"} summarizes the scores on the attitudinal items for the two groups, where answers were grouped in (completely) disagree, neutral and (completely) agree, in terms of percentages of respondents who agree (in most cases truly positive) and who provided a neutral score. For both the 'oneself' and the 'child' group, around 5% were truly negative about all statements. The respondents in the 'child' group were more positive overall regarding the attitudinal questions compared to the respondents in the 'oneself' group. Strikingly, a large proportion provided a neutral score on average over all items: 27% in the 'oneself' group and 22.3% in the 'child' group. With one exeption, these background variables did not provide relevant associations that could explain differences in decisions made in the DCE. The exception was in case of the 'oneself' group, where the item "If I do not have myself vaccinated, there is a good chance that I experience an infectious disease against which vaccination is done within the NIP" (risk perception), was important for explaining preference heterogeneity. Table 3Distribution of answers on attitudinal items by respondent in oneself and child groupStatement AdultStatement ChildAnswer range% \> 3 Oneself% neutral Oneself% \> 3 Child% neutral ChildI find vaccinating myself against infectious diseaseVaccinating my child following the NIP isVery unwise (1) -- very wise (5)79.214.881.912.6I find vaccinating myself against infectious diseaseVaccinating my child following the NIP isVery unimportant (1) - very important (5)78.316.483.012.6I find vaccinating myself against infectious diseaseVaccinating my child following the NIP isVery unnecessary (1) - very necessary (5)72.521.181.413.0People who are important to me, find that I have to vaccinate myselfPeople who are important to me, think that I have to vaccinate my childTotally disagree (1) - totally agree (5)46.539.356.933.4People who are important to me vaccinate themselvesPeople who are important to me vaccinate their child (ren)Totally disagree (1) - totally agree (5)57.333.671.922.2People who are important to me appreciate if I vaccinate myselfPeople who are important to me appreciate if I vaccinate my childTotally disagree (1) - totally agree (5)51.440.159.833.2If I do not have myself vaccinated, there is a good chance that I experience an infectious disease against which vaccination is done within the NIPIf I do not have my child vaccinated, there is a good chance that he / she will develop an infectious disease against which vaccination is done within the NIPTotally disagree (1) - totally agree (5)43.440.056.630.6The NIP is good for the protection of my own healthThe NIP is good for the protection of the health of my childTotally disagree (1) - totally agree (5)72.021.279.515.0I find it important that vaccinating myself contributes to the protection of othersI find it important that vaccinating my child contributes to the protection of othersTotally disagree (1) - totally agree (5)72.821.275.320.1The infectious diseases against which vaccination is carried out can be very severeThe infectious diseases against which vaccination is carried out can be very severeTotally disagree (1) - totally agree (5)79.517.082.814.4The adverse side-effects of the vaccinations within the NIP can be very severeThe adverse side-effects of the vaccinations within the NIP can be very severeTotally disagree (1) - totally agree (5)26.348.223.443.4Vaccinating myself is not something I have to think hard aboutVaccinating my child is not something I have to think hard aboutTotally disagree (1) - totally agree (5)72.819.275.615.8Vaccinating myself is self-evidentVaccinating my child is self-evidentTotally disagree (1) - totally agree (5)67.020.875.915.5If I have to decide now, I would vaccinate myselfIf I have to decide now, I would vaccinate my child following the NIPTotally disagree (1) - totally agree (5)70.420.079.114.0If I had to make an extra appointment with my healthcare provider for vaccination, that would be a reason not to get vaccinatedIf I had to make an extra appointment with my healthcare provider for vaccination, that would be a reason not to have my child (ren) vaccinatedTotally disagree (1) - totally agree (5)12.420.618.118.1I trust the information about vaccinations that I receive from the healthcare providerI trust the information about vaccinations that I receive from the healthcare providerTotally disagree (1) - totally agree (5)72.420.572.819.9I trust the information about vaccinations that I receive from the governmentI trust the information about vaccinations that I receive from the governmentTotally disagree (1) - totally agree (5)67.922.570.419.5It's everyone's responsibility to get vaccinatedIt's the responsibility of every parent to vaccinate their child (ren)Totally disagree (1) - totally agree (5)69.221.169.720.8I find it bad when others do not vaccinateI find it bad when other parents do not vaccinate their child (ren)Totally disagree (1) - totally agree (5)59.927.259.827.8Experiencing infectious diseases contributes to a positive mental and physical developmentExperiencing infectious diseases contributes to a positive mental and physical development of my childTotally disagree (1) - totally agree (5)30.140.133.435.2Experiencing infectious diseases leads to a better and life-long protection compared to vaccinationExperiencing infectious diseases leads to a better and life-long protection compared to vaccinationTotally disagree (1) - totally agree (5)29.842.234.130.7Wording of statements differs between the 'oneself' and 'child' groups. Items are scored on a 5-point Likert scale, with specific wording (see Answer range). Per group the percentages of respondents who provided a score larger than 3 and a neutral score of 3 are given

'Oneself' model {#Sec4}
---------------

For respondents in the 'oneself' group, vaccine effectiveness was the most important attribute in their vaccine decision, followed by burden of disease and accessibility, which were practically equally important (relative importance of 78 and 76% compared to vaccine effectiveness -- Fig. [1](#Fig1){ref-type="fig"}). Far less influential were population coverage and mild VRSE, with relative importance of 22 and 13%. Local coverage (5%) was ranked last, after several covariate interactions indicating preference heterogeneity. For both population and local coverage, respondents preferred a vaccine that has a high uptake already. In Table [4](#Tab4){ref-type="table"}, the estimates for the 'oneself' model are displayed, representing marginal utilities assigned to the different attribute levels. Noteworthy is that for burden of disease, the mild levels do not significantly differ (− 0.764 vs. -0.753), indicating no strong preference for one over the other. For all estimates hold that a more positive marginal utility translates to a more preferable vaccine profile. As described, burden of disease is expressed in terms of severity and susceptibility. The estimates show that severity is assigned more weight, indicating that a vaccine is preferred against a rare but severe disease over one that protects against a more frequent but mild disease. Fig. 1Importance of all statistically significant main and interaction effects (*p* \< 0.05) relative to the most important attribute 'vaccine effectiveness' ('oneself' model) and 'burden of disease' ('child' model)Table 4Panel mixed logit model estimates of the 'oneself' model: mean and standard deviation (std dev) and significance of the attribute effects obtained from likelihood ratio (LR) tests with specified number of degrees of freedom (DF)TermMean estimate (std dev; subject std dev)95% CIMarginal utilitiyLR Chi-squareDF*P*-value**Vaccine effectiveness** 50%−0.755 (0.039; 0.323)\[−0.833; − 0.682\]−0.7551383.1591\<.0001 90%0.755 (0.036; 0.293)\[0.685; 0.825\]0.7551**Burden of disease** Rare&mild−0.764 (0.080; 0.225)\[− 0.953; − 0.632\]−0.7642308.4823\<.0001 Common&mild−0.753 (0.079; 0.204)\[− 0.900; − 0.595\]−0.7533 Rare&severe0.351 (0.073; 0.144)\[0.201; 0.497\]0.3511 Common&severe1.166 (0.076; 0.180)\[1.018; 1.315\]1.1664**Mild VRSE** Common−0.210 (0.027; 0.102)\[− 0.264; − 0.159\]−0.210344.6571\<.0001 Rare0.210 (0.025; 0.106)\[0.160; 0.260\]0.2103**Accessibility** Co-payment prescription−0.608 (0.041; 0.240)\[− 0.691; − 0.533\]−0.6085288.6791\<.0001 Free accessible0.608 (0.044; 0.242)\[0.522; 0.695\]0.6085**Local coverage (×10%)**0.054 (0.012; 0.122)\[0.031; 0.078\]0.053815.0910.0001**Global coverage (× 10%)**0.125 (0.013; 0.160)\[0.101; 0.153\]0.124779.1011\<.0001**Burden of disease\*Educational level** Rare&mild\*Low0.503 (0.134; 0.247)\[0.254; 0.789\]−0.261738.0046\<.0001 Rare&mild\*Mid−0.099 (0.108; 0.283)\[− 0.291; 0.169\]−0.8635 Rare&mild\*High−0.403 (0.082; 0.182)\[−0.563; − 0.243\]−1.1675 Common&mild\*Low0.196 (0.132; 0.275)\[−0.046; 0.451\]−0.5572 Common&mild\*Mid−0.005 (0.098; 0.246)\[−0.195; 0.174\]−0.7586 Common&mild\*High−0.191 (0.094; 0.242)\[−0.375; − 0.006\]−0.9441 Rare&severe\*Low−0.174 (0.092; 0.180)\[−0.365; − 0.014\]0.1774 Rare&severe\*Mid0.182 (0.071; 0.134)\[0.053; 0.316\]0.5332 Rare&severe\*High−0.008 (0.091; 0.161)\[−0.186; 0.170\]0.3427 Common&severe\*Low−0.525 (0.094; 0.198)\[− 0.708; − 0.341\]0.6415 Common&severe\*Mid−0.078 (0.079; 0.167)\[−0.232; 0.077\]1.0888 Common&severe\*High0.602 (0.093; 0.200)\[0.419; 0.785\]1.7688**Burden of disease\*Being target group for influenza vaccination** Rare&mild\*Yes0.216 (0.067; 0.190)\[0.093; 0.359\]−0.548230.4723\<.0001 Common&mild\*Yes0.179 (0.072; 0.203)\[0.034; 0.313\]−0.5742 Rare&severe\*Yes−0.087 (0.063; 0.133)\[−0.217; 0.040\]0.2638 Common&severe\*Yes−0.308 (0.063; 0.149)\[−0.431; −0.184\]0.8586 Rare&mild\*No−0.216 (0.067; 0.145)\[−0.348; −0.084\]−0.9802 Common&mild\*No−0.179 (0.074; 0.187)\[−0.323; −0.035\]−0.9324 Rare&severe\*No0.087 (0.062; 0.116)\[−0.034; 0.209\]0.4384 Common&severe\*No0.308 (0.060; 0.132)\[0.191; 0.425\]1.4742**Accessibility\*Risk perception Low vs High** Co-payment\*Low0.158 (0.037; 0.256)\[0.091; 0.233\]−0.450018.3111\<.0001 Co-payment\*High−0.158 (0.037; 0.272)\[−0.231; −0.085\]−0.7669 Free\*Low−0.158 (0.043; 0.228)\[−0.242; −0.074\]0.4500 Free\*High0.158 (0.037; 0.253)\[0.087; 0.230\]0.7669Note: Mean estimates corresponding to the last level of an attribute were calculated as minus the sum of the estimates for the other levels of the attribute

With regard to preference heterogeneity evidenced by significant covariate interactions (Fig. [2](#Fig2){ref-type="fig"} and Table [4](#Tab4){ref-type="table"}), we found that respondents with a lower level of education attached less importance to the disease burden compared to those with a higher educational level. In the same line, respondents belonging to the target group for annual influenza vaccination (i.e., being over 60 years of age and/or having one or more chronic diseases) were less sensitive towards the disease burden compared to those who are not eligible. Another significant interaction involved the response to the statement 'The infectious diseases against which vaccination is carried out can be very severe (risk perception)' (79.5% of the subsample in the 'oneself' group). Respondents who did agree with this statement had stronger preferences for accessibility compared to those who did not agree. Fig. 2Marginal utilities for significant covariate interaction terms in the 'oneself' model. **a** Covariate interaction between burden of disease and educational level. **b** Covariate interaction between burden of disease and influenza riskgroup. **c** Covariate interaction between accessibility and disease risk perception

'Child' model {#Sec5}
-------------

The best fitting 'child' model differed slightly from the 'oneself' model. Vaccine effectiveness and burden of disease were considered equally important in the 'child' model (Fig. [1](#Fig1){ref-type="fig"}). In addition, accessibility and population coverage were of lower importance in the 'child' model than in the 'oneself' model, but local coverage was of higher importance. Table [5](#Tab5){ref-type="table"} presents marginal utility estimates, where, like in the 'oneself' model, the least attractive levels of vaccine effectiveness, burden of disease and accessibility all had a substantial negative effect on total utility, and vice versa for the most attractive levels. As in the 'oneself' model, the vaccines protecting against the more severe diseases are preferred over the mild variants. In contrast though, here a vaccine against a frequently occurring mild disease is significantly preferred over the rare mild variant. A 10% increase in population coverage led to a marginal utility increase of 0.112, implying that vaccines with a higher global coverage were preferred. In case of local coverage, the marginal utility was dependent on accessibility and mild VRSE, due to significant interaction effects. In both cases, we find a positive addition to the less preferable levels of VRSE (more VRSE) and accessibility (need for co-payment) when local coverage is high. Table 5Panel mixed logit model estimates of the 'child' model: mean and standard deviation (std dev) and significance of the attribute effects obtained from likelihood ratio (LR) tests with specified number of degrees of freedom (DF)TermMean estimate (std dev; subject std dev)95% CIMarginal utilityLR Chi-squareDF*P*-value**Vaccine effectiveness** 50%−0.970 (0.047; 0.366)\[−1.070; −0.888\]−0.9701382.0341\<.0001 90%0.970 (0.056; 0.380)\[0.861; 1.079\]0.9701**Burden of disease** Rare&mild−1.507 (0.154; 0.377)\[−1.811; −1.198\]−1.5066405.5163\<.0001 Common&mild−0.969 (0.105; 0.311)\[−1.179; −0.761\]−0.9686 Rare&severe0.683 (0.099; 0.175)\[0.458; 0.842\]0.6831 Common&severe1.792 (0.108; 0.506)\[1.580; 2.004\]1.7921**Mild VRSE** Common−0.518 (0.055; 0.116)\[−0.637; −0.417\]−0.517540.5691\<.0001 Rare0.518 (0.071; 0.120)\[0.379; 0.656\]0.5175**Accessibility** Co-payment prescription−0.971 (0.059; 0.177)\[−1.098; −0.870\]−0.9713154.2931\<.0001 Free accessible0.971 (0.092; 0.172)\[0.791; 1.152\]0.9713**Local coverage (× 10%)**0.115 (0.016; 0.172)\[0.084; 0.146\]0.114747.7911\<.0001**Global coverage (×10%)**0.112 (0.013; 0.141)\[0.086; 0.139\]0.111949.1121\<.0001**Mild VRSE\*Local coverage** Common\*Local coverage0.041 (0.010; 0.051)\[0.024; 0.061\]0.041213.52710.0002 Rare\*Local coverage−0.041 (0.012; 0.052)\[−0.064; −0.018\]−0.0412**Accessibility\*Local coverage** Co-payment\*local0.044 (0.009; 0.080)\[0.028; 0.063\]0.044420.1471\<.0001 Free\*local−0.044 (0.014; 0.085)\[−0.072; −0.017\]−0.0444**Burden of disease\*Risk of flu next 12 month (Low vs. high)** Rare&mild\*High−0.260 (0.112; 0.378)\[−0.471; −0.047\]−1.766419.79930.0002 Common&mild\*High−0.155 (0.093; 0.303)\[−0.371; 0.007\]−1.1238 Rare&severe\*High−0.003 (0.086; 0.156)\[−0.186; 0.145\]0.6803 Common&severe\*High0.418 (0.094; 0.367)\[0.234; 0.602\]2.2098 Rare&mild\*Low0.260 (0.104; 0.489)\[0.057; 0.463\]−1.2469 Common&mild\*Low0.155 (0.093; 0.245)\[−0.028; 0.338\]−0.8134 Rare&severe\*Low0.003 (0.098; 0.216)\[−0.189; 0.194\]0.6859 Common&severe\*Low−0.418 (0.094; 0.601)\[−0.602; −0.233\]1.3744**Burden of disease\*Information via internet (other than social media)** Rare&mild\*No0.427 (0.099; 0.475)\[0.251; 0.625\]−1.080018.54130.0003 Common&mild\*No0.007 (0.083; 0.256)\[−0.143; 0.184\]−0.9611 Rare&severe\*No−0.048 (0.075; 0.183)\[−0.182; 0.113\]0.6346 Common&severe\*No−0.386 (0.096; 0.416)\[−0.575; −0.196\]1.4066 Rare&mild\*Yes−0.427 (0.111; 0.296)\[−0.645; −0.208\]−1.9332 Common&mild\*Yes−0.007 (0.082; 0.189)\[−0.167; 0.152\]−0.9760 Rare&severe\*Yes0.048 (0.086; 0.204)\[−0.120; 0.217\]0.7316 Common&severe\*Yes0.386 (0.094; 0.306)\[0.202; 0.569\]2.1777Note: Mean estimates corresponding to the last level of an attribute were calculated as minus the sum of the estimates for the other levels of the attribute

With regard to preference heterogeneity among the parents in the 'child' group (Fig. [3](#Fig3){ref-type="fig"} and Table [5](#Tab5){ref-type="table"}), we found significant interactions between burden of disease and the perceived susceptibility of their child to influenza and, additionally, between burden of disease and using information about vaccination from the internet (other than social media). Respondents who perceived the risk of their child to get influenza in the next 12 months as high were more in favor of a vaccine against a common and severe disease for their child, but also more in disfavor of a vaccine against a rare and mild disease, compared to those who considered their child to be less vulnerable to influenza. A similar pattern was found for the interaction with vaccine information from the internet. Respondents who consulted internet sources (36.6%) showed a stronger preference for vaccination against the common and severe level, while being more negative towards vaccinating against a rare and mild disease. Fig. 3Marginal utilities for significant covariate interaction terms in the 'child' model. **a** Covariate interaction between burden of disease and risk of flu. **b** Covariate interaction between burden of disease and internet as source of information about vaccination (other than social media)

Discussion {#Sec6}
==========

We identified the most important attributes for vaccination decision-making among Dutch adults, both for vaccinating themselves and for vaccinating their child. We found slight differences between these two perspectives. Although decision-making in both groups was primarily driven by vaccine effectiveness, burden of disease was more important for those deciding for their child, compared to those making a decision for themselves. The attribute burden of disease was expressed both in terms of disease severity (impact) and susceptibility (disease frequency). Of these two elements, more weight was assigned to severity, based on the attribute level utility estimates. Irrespective of perspective, the frequency of mild VRSE, population coverage and local coverage among friends and family were relatively unimportant in the decision. When adults decided for themselves, there was no significant difference in utility between vaccinating against a common or rare mild disease. In case of the decision for their child, a vaccine against a common and mild disease was preferred over a vaccine that protects against a mild but rare disease.

We found covariate interactions that differed between the two groups, whereby being among the target group for the annual influenza vaccination was the strongest in the 'oneself' model. Understandably, for respondents receiving this invitation, the question to vaccinate oneself was possibly related to different experiences compared to respondents not receiving the invitation, as this group is more experienced with vaccination overall compared to adults who do not qualify for influenza vaccination, and probably only have experience with travel vaccines for themselves. Following this logic, it is also not unexpected that this covariate is not explaining differences within the 'child' model. Notably, this also has to do with selection effects, because belonging to the risk group, thus receiving yearly influenza vaccination, is less likely in the group of parents belonging to the child group.

Contrary to what we expected, we were not able to find differences in preferences between respondents belonging to the orthodox Protestant community and other respondents. It is possible that those who opt out of vaccination may have chosen not to cooperate in this survey in the first place. Furthermore, moderately negative attitudes among respondents about vaccination in general (Table [3](#Tab3){ref-type="table"}) may have been suppressed by the forced choice for either of two "pro-"vaccination options in the DCE section.

Attitudes towards vaccination are important determinants of vaccine acceptance and vaccine hesitancy \[[@CR6], [@CR8], [@CR9], [@CR11], [@CR47]\]. We found a considerable number of neutral responses on almost all items in the attitudinal questionnaire, ranging from 12.6 to 48.2%. This might indicate that most participants are passively accepting routinely offered vaccinations. This could be linked to the highly reported trust in both information received from healthcare providers and government (\> 70%). As described, all attitudinal items were used to assess preference heterogeneity and all, except for one in the 'oneself' model, showed no significant interactions in the joint models.

Of particular interest is the finding that the marginal utility estimates of the local (friends and family) and population coverage attributes were positive. This indicates that a vaccine is more likely to be accepted by an individual if others accept it too. A possible explanation is that individuals perceive a high coverage as a social norm or as public confidence in the vaccination programme. This link is also reported in Belgium \[[@CR24]\], Australia \[[@CR18]\], USA \[[@CR19]\] and South Africa \[[@CR23]\]. This observation is contrasting with the rational utility theory, which argues that when (enough) others are vaccinated you maximize your own utility by not vaccinating. Indeed, high coverages protect susceptible individuals via 'herd protection', without them being exposed to the (perceived) side-effects of vaccination \[[@CR16], [@CR17]\]. Furthermore, the observation that there is more willingness to vaccinate when acceptance at local or national level is high, is important in planning communication strategies about vaccination programmes. A message that the acceptance is high among those who have been offered vaccination recently may lead to a higher uptake among those who will be offered vaccination. Similarly, a message that the current coverage is low may lead to a lower uptake. Future studies should aim to quantify or further explain the relationship between reporting vaccination coverage and willingness to vaccinate. In the 'child' group, accessibility and mild VRSE significantly interacted with local coverage, making the effect of social influence even stronger. Both more common VRSE and vaccines that require co-payment were valued less negative if the local coverage was higher.

This study has several limitations. A first limitation is that although our sample was representative with respect to gender, age and province, there could be unmeasured differences between the respondents in our sample and the general population, for example due to higher computer access in the online panel. Moreover, the sample population in this study was higher educated compared to the population's educational level.

A potential weakness regarding the DCE is the sensitivity to the framing of the VRSE attribute. In the original study in Flanders, this attribute appeared most important in both the vaccination decision for oneself and one's child. In our DCE as well as in the South African DCE, this attribute was rephrased. Originally, the VRSE attribute did not provide any explanation with regard to severity of VRSE. Therefore, its description was changed such that it explicitly states that VRSE are of mild nature and rarely result in hospitalization. In our study, only the frequency of VRSE occurrence was varied. The differences in outcomes between our study and the South African study on the one hand, and the original Flemish study on the other, highlight the influence of framing, as well as being as specific as possible with regard to VRSE.

Another limitation is that due to the age structure of respondents with children under the age of 18, which are mostly between 25 and 40 years old, we observed a slight underrepresentation of this age group in the 'oneself' group. As a result, we cannot fully explore the differences between individuals with and without young children. However, given that we found only limited differences between the two vaccination decision-making settings and the large sample size, we do not expect that additional research would lead to different conclusions.

When the findings of this study are compared to both the Flemish and the South African study we find both similarities and differences. With regard to ranking of importance of the attributes the three studies all found different rank orders. As described, in the Flemish study VRSE combined with accessibility were the two most important attributes, followed by effectiveness and burden of disease. In South Africa, vaccine effectiveness was the most important attribute followed by population coverage and burden of disease. As in South Africa, here we found that vaccine effectiveness was the most important attribute, although in case of the child vaccination, this was combined with burden of disease. The importance of vaccine effectiveness was also found in other DCEs \[[@CR20], [@CR35], [@CR38]\]. Per study, the interaction terms indicating preference heterogeneity differed slightly. In both this study and the Flemish study it was found that there was preference heterogeneity related to age and burden of disease. In the Flemish study it was found that the older age groups are less sensitive to burden of disease, i.e. the estimates between the different levels do not vary much. Here, this was the case with regard to belonging to the 'influenza risk group', which is related to age. None of the studies found considerable differences between the decision to vaccinate oneself or one's child. Further, for all studies the estimates of the coverage attributes were positive, indicating that a higher coverage was preferred adding to evidence that decisions of peers are important. With regard to representation of the study population, all three studies struggled with underrepresentation of the groups with lower educational attainment.

Conclusions {#Sec7}
===========

We performed a discrete choice experiment in The Netherlands to gain insights into vaccination decision-making with respect to vaccinating oneself and one's child. Vaccine effectiveness, burden of disease and accessibility were the most important attributes in the decision-making process. Less influential, but still important contributors to vaccine utility were the population and local coverage. For both coverage attributes, we found positive utility estimates, indicating the effect of social influence. In the decision to vaccinate one's child, estimates were even larger in absolute magnitude due to interactions with mild VRSE and accessibility, where higher local coverage increased the utility in magnitude for the least desirable options (i.e. common VRSE and co-payment). Our findings indicate that the focus of communication about vaccination is similar for vaccinating children and oneself. The message should stress the effectiveness and low effort of vaccination and clearly explain the burden of disease against which vaccines protect. Reporting high uptake rates may help to increase uptake of vaccination in future vaccination decisions.
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**Additional file 1.** DCE Questionnaire

DCE

:   Discrete choice experiment

LR

:   Likelihood Ratio

NIP

:   National Immunization Program

PML

:   Panel Mixed Logit

RI

:   Relative Importance

SBSQ

:   Set of Brief Screening Questions

VRSE

:   Vaccine-related side effects
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